spacer
home > pmps > spring 2018 > fight against counterfeit drugs
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Fight Against Counterfeit Drugs

Among the myriad of challenges faced by the pharmaceutical industry, the challenge of counterfeit drugs is probably the greatest. It not only causes tremendous revenue losses, but also negatively impacts a company’s reputation and brand image. Most importantly, the miseries inflicted by it on human life are simply incalculable.

Counterfeit drugs are not only threatening the confidence in healthcare professionals and health programmes, but they are also increasing the burden on healthcare systems, national medicine regulatory authorities, law enforcement, and criminal justice systems. According to industry estimates, counterfeit medicines sales are ranging from €150-€200 billion (US$163-$217 billion) per year (1). To counter this increasing threat, government bodies in most countries are devising more robust and strict regulations to control the genesis and proliferation of fake medicines. Track-and-trace, along with pharma product serialisation, is the next firm step towards winning this fight.

The Increasing Serialisation Trend

Serialisation entails encoding of each pharma product coming off a packaging line with a unique identification code that can be traced at each point throughout the supply chain. The unique identification code can be stored into an online database along with the other valuable information about the product, such as manufacturer and batch details, thus allowing for monitoring and tracing the journey of each product, from packaging line right up to the patient. Currently, serialisation regulations are at different phases of development in various countries. To match these country-specific deadlines, most of the global pharma companies need to be track-and-trace- and serialisation-ready.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gaurav Mohite at ACG Inspection Systems has over six years of expertise in holistic track-andtrace solutions for the pharma industry. He was part of the complete trackand- trace implementation team across all the ACG implementation globally. Gaurav had completed his master’s for Jamnalal Bajaj Institute of Management Studies, India, in marketing and bachelor degree in engineering. At the early stage of his professional career, he had worked on vision inspection systems and track-and-trace applications as developer and business analyst throughout the industry. Gaurav is currently working as product manager and working for product marketing, strategy planning, and technologic innovations.
spacer
Gaurav Mohite
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ChemAxon and AWS simplify getting scientists moving on the cloud

Listen to a talk by Paul Underwood of AWS introducing Biotech Blueprint, a cloud based solution for cheminformatics. The technology for novel compound registration is provided by ChemAxon.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

Clinical Innovation Partnerships 2018

3-4 July 2018, Radisson Blu Hotel, Zurich Airport

Clinical Innovation Partnerships is the only event for senior clinical operations and procurement professionals driving innovation in their clinical trials. It is where the pharma, CRO and vendor clinical trials ecosystem meet to drive innovation in digitalisation, tech and partnering to improve patient experience and reduce trial cost and time.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement